The HER2 antibodies industry continues to gain momentum as targeted cancer therapies become increasingly important in modern oncology treatment protocols. Growing prevalence of HER2-positive cancers, especially breast and gastric cancers, has accelerated the adoption of advanced biologic therapies across developed and emerging healthcare systems. Pharmaceutical companies and biotechnology...